Hong Kong Stock Movement | Henlius Biotech (02696.HK) Opens Over 4% Higher as PD-L1/VEGF Bispecific Antibody Initiates Phase 2/3 Clinical Trial for First-Line NSCLC

Zhito Finance APP has learned that Henlius Biotech (02696.HK) opened more than 4% higher. As of press time, it was up 4.64%, at HK$53.0, with a turnover of HK$47,700.